Drug development

      BC: breast cancer; CIBL: cancer-induced bone loss;  Col. cancer: colon cancer; OvC: ovarian cancer

Alethia’s pipeline places great emphasis on the development of monoclonal antibodies that were generated against therapeutic targets revealed using its integrated discovery and validation platform. Two monoclonal antibody lead candidates are under evaluation as inhibitors of osteoclast differentiation and tumor progression in our severe bone loss and ovarian cancer programs, respectively. Furthermore, a monoclonal antibody for the treatment of metastatic cancer is currently being examined in animal models of metastatic breast cancer. Finally, isogranulatimide, a small molecule checkpoint inhibitor, is the most advanced product with an expected IND filing in 2009.

1. Drug pipeline
   

2. Anti-clusterin mAb
   

3. Checkpoint inhibitor
   

4. Other lead targets

CONTACT US

FRANÇAIS

HOME

About us

Discovery programs

Drug development

Business development

Media center

Copyright © 2002-2008 Alethia Biotherapeutics Inc. All rights reserved.